Project Grant R01CA295865
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $680K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award of $155,500 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports the establishment of an in-vivo Sleeping-Beauty screen to identify and characterize novel drivers of melanomagenesis in a nevi-prone zebrafish model. The research aims to address the knowledge gap in understanding the transcriptional mechanisms, outside of somatic mutations, that are necessary for melanocyte transformation and melanoma...
- The President and Fellows of Harvard College, through its Harvard Medical School division, was awarded a $124,459 Project Grant from the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program. The grant, awarded on December 1, 2024, supports research to investigate the role of the Microphthalmia-associated transcription factor (MITF) and growth factors in initiating melanoma, the deadliest form of skin cancer. The research utilizes a zebrafish model to study the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $223,176 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct research on the role of stress granules in cancer initiation and progression. The overarching goal is to use a humanized zebrafish melanoma model to investigate how stress granules formed in melanoma precursor cells impact tumor development and oncogenicity. Specific objectives...
- This Project Grant award of $395,509 from the National Cancer Institute's Cancer Biology Research Program (CFDA 93.396) supports research by the Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The project aims to investigate the regulatory mechanisms and pathological roles of the SKP2 oncogenic E3 ubiquitin ligase in melanoma development and progression. Specifically, the research seeks to: 1) understand how SKP2 protein stability is regulated by its upstream E3...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $487,468 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the role of protein palmitoylation in the progression of melanoma lung metastasis. The key objectives of the research project are to: Investigate how the palmitoyl transferase ZDHHC13 suppresses melanoma metastasis by stabilizing E-cadherin through palmitoylation...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $510,431 Project Grant to The Johns Hopkins University to conduct research on recurrence and resistance in the aging melanoma microenvironment. The research aims to uncover how the aging immune microenvironment influences tumor dormancy and therapeutic resistance in melanoma. Key focus areas include understanding the role of aged lung fibroblasts and their impact on melanoma cell dormancy and reactivation through Wnt...
- This $463,375 federal Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The research aims to identify and characterize the role of melanin-carbonyl-DNA (MCD) and melanin-carbonyl-protein (MCP) adducts in the progression and treatment resistance of NRAS mutant melanoma. The key objectives are to...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $442,236 to the University of Alabama at Birmingham (UAB) from January 1, 2025 through December 31, 2029. The funding supports research to uncover a novel melanoma metastasis pathway driven by the YTHDF1 RNA-binding protein, and to evaluate therapeutic targeting of the IMPDH1 and TRKB/BDNF pathways that mediate this process. The research utilizes...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $799,107 Project Grant to the Dana-Farber Cancer Institute, Inc. in Boston, MA to conduct research on using genomic biomarkers and decision analysis frameworks to guide treatment decisions for stage III melanoma patients. The grant will fund a collaborative project involving researchers from Dana-Farber and Brigham & Women's Hospital to develop methods for translating genomic and...
- The Department of Defense's Defense Health Agency has awarded a $1,258,719 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant, awarded on July 15, 2024, will support a 3-year research project titled "Melanoma Chemoprevention via Neuropilin-2 Axis Blockade." Through this grant, Boston Children's Hospital will conduct biomedical research focused on...